首页> 外文期刊>The lancet oncology >Validity of adjuvant! Online program in older patients with breast cancer: A population-based study
【24h】

Validity of adjuvant! Online program in older patients with breast cancer: A population-based study

机译:佐剂的有效性!老年乳腺癌患者在线计划:一项基于人群的研究

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Adjuvant! Online is a prediction tool that can be used to aid clinical decision making in patients with breast cancer. It was developed in a patient population aged 69 years or younger, and subsequent validation studies included small numbers of older patients. Since older patients with breast cancer differ from younger patients in many aspects, the aim of this study was to investigate the validity of Adjuvant! Online in a large cohort of unselected older patients. Methods: We included patients from the population-based FOCUS cohort, which included all consecutive patients aged 65 years or older who were diagnosed with invasive or in-situ breast cancer between Jan 1, 1997, and Dec 31, 2004, in the southwestern part of the Netherlands. We included all patients who fulfilled the criteria as stated by Adjuvant! Online: patients with unilateral, unicentric, invasive adenocarcinoma; no evidence of metastatic or residual disease; no evidence of T4 features; and no evidence of inflammatory breast cancer. We entered data from all patients with the "average for age" comorbidity status (model 1) and with an individualised comorbidity status (model 2). Findings: We included 2012 patients. Median age of patients in the cohort was 74·0 years (IQR 69·0-79·0). 904 (45%) of 2012 patients died during follow-up, whereas 326 (16%) patients had recurrence. Median follow-up for overall survival was 9·0 years (IQR 7·4-10·7), and 6·6 years (4·4-6·6) for patients without recurrence. Using model 1, Adjuvant! Online overestimated 10-year overall survival by 9·8% ([95% CI 5·9-13·7], p<0·0001) and 10-year cumulative recurrence survival by 8·7% ([6·7-10·7], p<0·0001). By contrast, when using model 2, Adjuvant! Online underestimated the 10-year overall survival by -17·1% ([95% CI -21·0 to -13·2], p<0·0001). However, when using model 2, Adjuvant! Online predicted cumulative recurrence accurately in all patients (-0·7% [95% CI -2·7-1·3], p=0·48). Interpretation: Adjuvant! Online does not accurately predict overall survival and recurrence in older patients with early breast cancer. Funding: Dutch Cancer Foundation.
机译:背景:佐剂!在线是一种预测工具,可用于辅助乳腺癌患者的临床决策。它是针对年龄在69岁以下的患者开发的,随后的验证研究包括少数老年患者。由于老年乳腺癌患者在许多方面都与年轻患者不同,因此本研究的目的是研究佐剂的有效性!大量未选老年患者的在线研究。方法:我们纳入了基于人群的FOCUS队列中的患者,该患者包括1997年1月1日至2004年12月31日期间在美国西南部连续被诊断为浸润性或原位乳腺癌的所有65岁以上患者荷兰的。我们纳入了所有符合佐剂标准的患者!在线:单侧,单中心,浸润性腺癌患者;没有转移或残留疾病的证据;没有T4特征的证据;也没有炎症性乳腺癌的证据。我们从“平均年龄”合并症状态(模型1)和个体化合并症状态(模型2)的所有患者输入数据。结果:我们纳入了2012年的患者。该队列患者的中位年龄为74·0岁(IQR 69·0-79·0)。 2012年有904名患者(45%)在随访期间死亡,而326名患者(16%)复发。中位随访时间为9·0年(IQR 7·4-10·7),无复发患者为6·6年(4·4-6·6)。使用模型1,佐剂!在线高估了10年整体生存率9·8%([95%CI 5·9-13·7],p <0·0001)和10年累积复发生存率8·7%([6·7- 10·7],p <0·0001)。相反,使用模型2时,佐剂!在线低估了10年的总体生存率-17·1%([95%CI -21·0至-13·2],p <0·0001)。但是,使用模型2时,佐剂!在线准确预测所有患者的累积复发率(-0·7%[95%CI -2·7-1·3],p = 0·48)。解释:佐剂!在线无法准确预测老年早期乳腺癌患者的总体生存率和复发率。资金来源:荷兰癌症基金会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号